IKNA vs. SPRO, VOR, IVA, XLO, GTHX, STRO, ENTA, ACB, SCLX, and ADCT
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Spero Therapeutics (SPRO), Vor Biopharma (VOR), Inventiva (IVA), Xilio Therapeutics (XLO), G1 Therapeutics (GTHX), Sutro Biopharma (STRO), Enanta Pharmaceuticals (ENTA), Aurora Cannabis (ACB), Scilex (SCLX), and ADC Therapeutics (ADCT). These companies are all part of the "medical" sector.
Spero Therapeutics (NASDAQ:SPRO) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
Spero Therapeutics has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.
Spero Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 387.80%. Ikena Oncology has a consensus price target of $3.00, suggesting a potential upside of 76.47%. Given Ikena Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Spero Therapeutics is more favorable than Ikena Oncology.
Spero Therapeutics has higher revenue and earnings than Ikena Oncology. Ikena Oncology is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ikena Oncology had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 3 mentions for Ikena Oncology and 2 mentions for Spero Therapeutics. Ikena Oncology's average media sentiment score of 1.48 beat Spero Therapeutics' score of 1.44 indicating that Spero Therapeutics is being referred to more favorably in the media.
25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are held by institutional investors. 4.5% of Spero Therapeutics shares are held by insiders. Comparatively, 5.9% of Ikena Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Spero Therapeutics received 173 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 69.31% of users gave Spero Therapeutics an outperform vote while only 59.57% of users gave Ikena Oncology an outperform vote.
Spero Therapeutics has a net margin of 21.09% compared to Spero Therapeutics' net margin of 0.00%. Ikena Oncology's return on equity of 35.42% beat Spero Therapeutics' return on equity.
Summary
Spero Therapeutics beats Ikena Oncology on 13 of the 17 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IKNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ikena Oncology Competitors List
Related Companies and Tools
